Apollomics Reports First-Half 2026 Financial Results
Key Highlights
- ➤$1.0 million cash at June 30, 2026, down from $3.3 million
- ➤$10.0 million private placement announced in August 2026
- ➤First-half net loss $8.8 million, versus $12.5 million in 2025
- ➤R&D expenses $2.0 million, down from $4.6 million
- ➤G&A expenses $4.5 million, down from $14.5 million
* Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. FOSTER CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2026 ended June 30, 2026.
Pipeline Update * Tumor Inhibitor * Vebreltinib (APL-101) – a highly specific, CNS-penetrant c-MET inhibitor for treating NSCLC, brain tumors, and other solid tumors with MET dysregulation. It also shows significant potential in combination regimens, particularly with EGFR inhibitors.
Get started
Create a free account to read the full story.